Ivaoes Animal Health launches new anesthetic product, Rapanofal (propofol emulsion injection), the only FDA-approved propofol product formulation indicated for use in cats and dogs.
Ivaoes Animal Health, LLC., a subsidiary of Tri-Source Pharma, LLC, announced the launch of Rapanofal (propofol emulsion injection)—the only product formulation approved for both dogs and cats.
Ivaoes Animal Health is a veterinary pharmaceutical manufacturer whose objective is to identify, develop, and distribute FDA-approved drugs for use in animals, targeting the medically critical pharmaceuticals with limited availability in the veterinary healthcare market.
“For many years, the veterinary industry has remained reliant on the human market for specialty drugs such as propofol,” said Robert DiCrisci, Ivaoes chairman and CEO. “With Rapanofal (Propofol), we have demonstrated our commitment to develop and commercialize high quality products, providing our veterinary customers with what they need when treating their animal patients. We are excited about our recent developments and are looking forward to the expansion of our pharmaceutical product line. In addition to this new product development, we have commissioned our EVP and chief commercial officer, Richard Dinovitz, to head up all animal health sales and commercialization efforts.”
Rapanofal (propofol) contains the only FDA-approved propofol formulation on the market with both a feline and canine indication. The drug offers veterinarians both a reliable supply and the convenience of dosing both feline and canine patients.
Ivaoes Animal Health says it provides competitive pricing, flexibility and ample product allocation to mitigate the recurring short supply events in the industry.
(Source: Business Wire)